Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24145355 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL6475002 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL17928956 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL20329541 | 1.00 | POLB (0.38) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL10440862 | 0.88 | CHRM2 (0.42) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL30454878 | 0.88 | POLB (0.35) | POLBGAACHRM2CHRM1KMT2A | |
| SCHEMBL29189673 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL14627937 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL24752585 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL29189672 | 0.82 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118894896-A | Method for preparing nematodoside and xyloside dimeric pheromone | 云南大学 | 2024-11-05 | — | — | CN | claimed |
| WO-2023278827-A1 | 3-IODOPROPYL-1,2,3-TRIAZOL-1-YL, 3-BROMOPROPYL-1,2,3-TRIAZOL-1-YL, AND DERIVATIVES FOR USES IN LABELING | EMORY UNIVERSITY (US) | 2023-01-05 | — | — | WO | claimed |
| EP-2091941-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-26 | — | — | EP | claimed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | claimed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | claimed |
| EP-4701666-A1 | ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | Iksuda Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4694936-A1 | STEAP2 ANTIBODY DRUG CONJUGATES AND USES THEREOF | MedImmune, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4661912-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | Pinotbio, Inc. (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-4651911-A1 | NEW SENESCENCE TRACER GENERATION | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2025-11-26 | — | — | EP | disclosed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4583870-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Mito Biopharma, LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025124456-A1 | ANTIBODY DRUG CONJUGATE PLATFORMS | BEIGENE, LTD. (KY) | 2025-06-19 | — | — | WO | disclosed |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2091941-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20090176859-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176859-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | POLB 1348/4885GAA 308/4885CHRM2 2352/4885 |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | POLB 1774/4885GAA 2792/4885CHRM2 4693/4885 |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | POLB 1774/4885GAA 2792/4885CHRM2 4693/4885 |
| US-20090176859-A1 | Cathepsin cysteine protease inhibitors | CTSE, CTSB, CTSS | POLB 3690/4885GAA 549/4885CHRM2 941/4885 |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK6, MAPK4 | POLB 2121/4885GAA 2772/4885CHRM2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.